Citius Pharmaceuticals Inc (CTXR) Stock Price, Quote & News

Company Profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic reli...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 967 6677

Website: citiuspharma.com

Address:

11 Commerce Drive, First Floor, Cranford, United States

donein12 May. 13 at 10:13 AM

$CTXR Per Charles Schwab: Next earnings date 05/13/2026 Time of release Before market open

0 · Reply

InvestorRelations_ May. 12 at 9:46 AM

$CTXR can someone please remind me quick how Mazur fucked us over when the vote to issue more shares fell through? That fucker somehow converted some shares so he essentially diluted us anyway? What was that again?

1 · Reply

Waffels May. 11 at 7:14 PM

$CTXR big things are coming mark my words

0 · Reply

Cooch23 May. 11 at 12:24 AM

$CTXR so in theory, revenue won’t show until 3q

0 · Reply

RME47pilot May. 9 at 10:28 AM

$CTXR this company and stock is pure junk. save money and avoid this dumpster fire. you have a better chance of making money if you simply burned your cash than hope CTXR would do something productive for shareholders.

0 · Reply

focafoca99 May. 8 at 9:06 PM

$CTXR restructured its promissory note, adding a conversion feature and extending the maturity date. https://www.rapidticker.com/news/ctxr-sec-filing-cfce3d

0 · Reply

TwongStocks May. 8 at 8:51 PM

$CTXR $CTOR One interesting feature of the third amendment. CTXR could acquire more shares of CTOR by converting a portion of the $3.8M Note into shares of CTOR at $0.90 per share. : "voluntary conversion feature allowing the Company, subject to Citius Oncology’s approval, to convert all or a portion of the outstanding principal into shares of common stock at a conversion price equal to $0.90 per share. All other terms of the Promissory Note remain the same." Full conversion of the $3,800,111 at $0.90 would be an additional 4,222,345 shares to CTXR.

1 · Reply

TwongStocks May. 8 at 8:42 PM

$CTXR SEC filing https://www.sec.gov/ix?doc=/Archives/edgar/data/1506251/000121390026053916/ea0289731-8k_citius.htm Summary • After the spinoff, CTXR gave $CTOR $3,800,111 in the form of a promissory note. • CTOR was originally supposed to repay CTXR after raising at least $10M. It was later revised to repayment after CTOR raised at least $30M in total funding. Then it was revised so that repayment would happen after CTOR raised at least $50M in total funding. • This third amendment now changes the repayment date to 91 days after CTOR pays off their loans to Avenue.

0 · Reply

Omarrr69 May. 7 at 1:48 PM

$CTXR tha ks God i sold from 67 cents 🥲🥲🥲 bro wtf is thissss

1 · Reply

Omarrr69 May. 7 at 1:29 PM

$CTXR 30 -40 cents upcoming then rs in june

0 · Reply

Market Cap	14.29M
Revenue (ttm)	0.00
Net Income (ttm)	-37.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	706,500
Avg Vol	807,326
Day's Range	N/A - N/A
Shares Out	22.38M
Stochastic %K	8%
Beta	1.05
Analysts	Sell
Price Target	$6.00